Bioray Biotech Co (7561) Fair Value & Analysis
Healthcare · TW · Market cap 605M TWD
Fair value as of: Jul 23, 2026
From 26 valuation models · updated 18 days ago
Share price −9.1% over the past month.
A strong business, screening 33% undervalued on our models.
What matters now
- The rarer combination: high quality (84/100) AND below fair value. That earns a closer look rather than a quick verdict.
- Our model range runs from 16.35 TWD (bear) to 27.25 TWD (bull), base 21.80 TWD. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 84/100 (high quality) with high evidence: the data supports the verdict.
Price vs Fair Value (8 months)
White line = price, green steps = our fair value per fiscal year. As of Jul 23, 2026.
How to read this chart
8‑month range 16.45 TWD – 26.00 TWD · fair‑value band 16.35 TWD – 27.25 TWD · the 16.45 TWD price screens below the 21.80 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Jul 23, 2026.
Analysis
Bioray Biotech Co (7561) currently trades at 16.45 TWD, while our model-based Fair Value estimate is 21.80 TWD, implying the stock looks roughly 32.5% undervalued today. The Quality Score stands at 84/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Bioray Biotech Co generated revenue of 230M TWD at a net margin of 13.3%. Revenue grew 33.0% year over year. It earns a return on equity of 7.1%. The balance sheet holds a net cash position of 92.4M TWD. Fundamentals as of Jul 23, 2026
Our scenario range runs from 16.35 TWD (bear case) to 27.25 TWD (bull case); at 16.45 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 37% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 33%, 7561 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (33.09 TWD) versus Dividend Discount (2.44 TWD). Highest evidence: Growth DCF (80).
Notify me when 7561 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 82 · Market factors (momentum, volatility) 28
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Bioray Biotech Co., Ltd engages in the production, research, and sells health foods, immune cell products, and precision testing services in Taiwan.
Full company description
Bioray Biotech Co., Ltd engages in the production, research, and sells health foods, immune cell products, and precision testing services in Taiwan. It offers health care products, including various functional foods and supplements; medicinal fungi; immune cell products; and precision medicine services, such as immunology, cell division, and specialized laboratory testing. The company is also involved in the cell testing and storage business. Bioray Biotech Co., Ltd was founded in 2005 and is based in Tainan City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Bioray Biotech Co reported revenue of 223M TWD in FY2025 versus 148M TWD in FY2021, a compound +10.8%/yr. Reported net income was 32.3M TWD in FY2025.
Watch 7561: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 624 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Bioray Biotech Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Bioray Biotech Co (7561) overvalued or undervalued?
What is the fair value of 7561?
What is the quality score of 7561?
What is the revenue of Bioray Biotech Co (7561)?
What is the net profit margin of 7561?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Bioray Biotech Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.